- Home
- NXT vs JAZZ Comparison
NXT vs JAZZ Comparison
Compare NXT & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXT | JAZZ |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 16.1B |
| IPO Year | 2023 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NXT | JAZZ |
|---|---|---|
| Price | $79.30 | $230.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 14 |
| Target Price | $115.67 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 1.8M | 584.9K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.66 | N/A |
| EPS | 1.07 | ★ 7.17 |
| Revenue | ★ $3,559,390,000.00 | $1,618,693,000.00 |
| Revenue This Year | $19.76 | $6.22 |
| Revenue Next Year | $11.96 | $7.68 |
| P/E Ratio | $73.95 | ★ $33.23 |
| Revenue Growth | ★ 20.28 | N/A |
| 52 Week Low | $73.07 | $128.80 |
| 52 Week High | $163.13 | $266.38 |
Technical Indicators
Market Signals| Indicator | NXT | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 39.59 | 35.84 |
| Support Level | $77.86 | $222.49 |
| Resistance Level | $87.82 | $242.66 |
| Average True Range (ATR) | 3.51 | 4.97 |
| MACD | 0.41 | -0.79 |
| Stochastic Oscillator | 30.77 | 2.64 |
Price Performance
Historical ComparisonAbout NXT Nextracker Inc.
Nextpower (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextpower's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextpower has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.